Kei Muro

Okazaki, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 417 publications

Clinical practice guidelines for duodenal cancer 2025.

Clinical practice guidelines for duodenal cancer 2025.

Journal: Journal of gastroenterology

Published: July 31, 2026

Correction: An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study.

Correction: An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study.

Journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association

Published: June 18, 2026

Systemic therapy for esophageal adenocarcinoma:current status and challenges of targeted therapy and immunotherapy

Systemic therapy for esophageal adenocarcinoma:current status and challenges of targeted therapy and immunotherapy

Journal: Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology

Published: June 10, 2026

Phase II study of mFOLFOX6 in advanced gastric cancer patients with severe peritoneal metastases (WJOG10517G), including an individual patient data comparison with JCOG1108/WJOG7312G.

Phase II study of mFOLFOX6 in advanced gastric cancer patients with severe peritoneal metastases (WJOG10517G), including an individual patient data comparison with JCOG1108/WJOG7312G.

Journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association

Published: April 28, 2026

A prospective, multicenter, observational study of trastuzumab deruxtecan in elderly patients with HER2-positive gastric cancer: EN-COURAGE.

A prospective, multicenter, observational study of trastuzumab deruxtecan in elderly patients with HER2-positive gastric cancer: EN-COURAGE.

Journal: ESMO gastrointestinal oncology

Published: April 17, 2026

Phase II basket study of brigatinib for ALK fusion-positive solid tumors: WJOG15221M/ALLBREAK (a decentralized clinical trial design).

Phase II basket study of brigatinib for ALK fusion-positive solid tumors: WJOG15221M/ALLBREAK (a decentralized clinical trial design).

Journal: Future oncology (London, England)

Published: April 15, 2026

Survival in Patients With Low Expression of Wild-Type Homologous Recombination Genes: Refining the Homologous Recombination Paradigm in Colorectal Cancer.

Survival in Patients With Low Expression of Wild-Type Homologous Recombination Genes: Refining the Homologous Recombination Paradigm in Colorectal Cancer.

Journal: JCO precision oncology

Published: April 03, 2026

Readministration of nivolumab for patients with advanced gastric cancer: a case series.

Readministration of nivolumab for patients with advanced gastric cancer: a case series.

Journal: ESMO gastrointestinal oncology

Published: February 26, 2026

Atezolizumab with or without tiragolumab in unresectable esophageal squamous cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study.

Atezolizumab with or without tiragolumab in unresectable esophageal squamous cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 19, 2026

Prognostic factors and treatment response in HER2-positive gastric cancer patients receiving trastuzumab deruxtecan: secondary analysis of the EN-DEAVOR study.

Prognostic factors and treatment response in HER2-positive gastric cancer patients receiving trastuzumab deruxtecan: secondary analysis of the EN-DEAVOR study.

Journal: ESMO gastrointestinal oncology

Published: February 06, 2026

WJOG18524G: a single-arm phase II study evaluating bemarituzumab combined with ramucirumab and paclitaxel in fibroblast growth factor receptor 2b (FGFR2b)-positive advanced gastric or gastroesophageal junction cancer (RAINBIRD).

WJOG18524G: a single-arm phase II study evaluating bemarituzumab combined with ramucirumab and paclitaxel in fibroblast growth factor receptor 2b (FGFR2b)-positive advanced gastric or gastroesophageal junction cancer (RAINBIRD).

Journal: ESMO gastrointestinal oncology

Published: February 06, 2026

Development of a visualization tool to estimate out-of-pocket costs for systemic cancer therapy in Japan and claims-based agreement evaluation: the VEST-Ca study.

Development of a visualization tool to estimate out-of-pocket costs for systemic cancer therapy in Japan and claims-based agreement evaluation: the VEST-Ca study.

Journal: Japanese journal of clinical oncology

Published: February 05, 2026

Showing 1-12 of 417

Last Updated: 09/26/2026